AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00433004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plan B (Levonorgestrel)
Description: PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
Study NCT04860388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed eruption technique
Description: The impacted teeth treated with closed eruption technique firstly. Orthodontic traction started a week later the sutures were removed. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch using double-arch technique. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, and keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The measurements compared with the contralateral canines that served as control teeth.
Study NCT02597478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray
Description: Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
Study NCT02597478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shuttle Walk Test
Description: Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
Study NCT02597478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
Study NCT02597478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Ability Tests
Description: After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
Study NCT02597478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Thirty days study visit participant called by study staff. This call should last about 10 minutes.
Study NCT02225691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired testing of blood glucose Accu-Chek®
Description: Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
Study NCT04097964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief intervention
Description: 1 minute or less of anticipatory guidance will be provided for adolescents reporting no use in the past year, a 3-5 minute abbreviated brief intervention including raising the subject, asking more questions, and correcting misinformation will be provided for adolescents reporting substance use once or twice in the past year, and a 5-10 minute full brief intervention will be provided, including the above steps as well as assessing readiness and negotiating change and scheduling a follow-up to potentially include a referral to treatment will be provided to adolescents reporting monthly to weekly use in the past year.
Study NCT04097964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: standard care conducted by primary care providers during clinic visits
Study NCT01359085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
Study NCT01359085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISBPB - interscalene brachial plexus block
Description: ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
Study NCT05337839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: home exercises
Description: stretching, balance and strengthening exercises
Study NCT05337839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: home exercises
Description: stretching, balance and strengthening exercises
Study NCT03128125 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clinical examination in neurology
Description: This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
Study NCT03128125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical examination in neurology
Description: This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
Study NCT03128125 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological examination
Description: This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
Study NCT03128125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological examination
Description: This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
Study NCT03128125 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: anamnestic elements
Description: Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
Study NCT03128125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anamnestic elements
Description: Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
Study NCT01837823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
Study NCT02238652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication
Description: A preparation process before the patient become incapable of participating in life prolonging decisions
Study NCT02238652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Pain Assessment and Treatment
Description: Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
Study NCT02238652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Review
Description: An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
Study NCT02238652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
Study NCT02238652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety
Description: Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
Study NCT01873534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-8
Description: FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
Study NCT00823615 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use
Study NCT00823615 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use
Study NCT03136848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normothermic ex-vivo kidney perfusion Solution -Toronto
Description: The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney.
Study NCT01765972 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon
Description: contact lens with Lacreon
Study NCT01765972 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with Lacreon with print
Description: contact lens with Lacreon and cosmetic print
Study NCT01765972 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print
Description: contact lens with print
Study NCT01765972 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacles (habitual)
Description: Spectacles
Study NCT01146743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gallbladder drainage
Description: EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
Study NCT01146743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous transhepatic gallbladder drainage
Description: Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
Study NCT00955916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG Regimen
Description: The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
Study NCT00955916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec®
Description: Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
Study NCT01934595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beneprotein
Description: The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
Study NCT01934595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneprotein
Description: The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
Study NCT00444145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevacid
Description: 30 mg bid for 3 months
Study NCT00444145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal and Laryngeal Biopsies
Description: repeat egd with biopsy after Prevacid 30 mg bid for 3 months
Study NCT04271722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical ripening
Description: Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
Study NCT04271722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical ripening
Description: Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
Study NCT03831451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke preparedness intervention
Description: Face-to-face interaction with research staff lasting between 5-10 minutes
Study NCT03831451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle stroke risk reduction intervention
Description: Face-to-face interaction with research staff lasting between 5-10 minutes
Study NCT01505530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
Study NCT01505530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
Study NCT01505530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
Study NCT01505530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Chemotherapy
Description: Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
Study NCT00845156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid
Description: Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
Study NCT00845156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha Lipoic Acid
Description: Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
Study NCT04270305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orientation
Description: In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.
Study NCT04270305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking
Description: In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
Study NCT00302705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan, Enalapril
Description: 160 mg valsartan versus 10-20 mg enalapril
Study NCT00302705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
Study NCT00302705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Missing one dose
Description: Patients skip the dose the second day of monitoring
Study NCT02528760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaclopramide
Description: 23. Metoclopromide to be given 10mg iv 8 hourly
Study NCT02528760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin to be given 70mg iv 12 hourly.
Study NCT02528760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00677118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin,fluorouracil
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
Study NCT00677118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
Study NCT01141465 — intervention group
Intervention type: DRUG
Intervention: Fluticasone / formoterol metered dose inhaler
Description: Prescribed at the same BDP-equivalent dose as baseline ICS
Study NCT01141465 — intervention group
Intervention type: DRUG
Intervention: Fluticasone / salmeterol dry powder inhaler
Description: Prescribed at the same BDP-equivalent dose as baseline ICS
Study NCT01141465 — intervention group
Intervention type: DRUG
Intervention: Budesonide / formoterol dry powder inhaler
Description: Prescribed at the same BDP-equivalent dose as baseline ICS
Study NCT01141465 — intervention group
Intervention type: DRUG
Intervention: Fluticasone / salmeterol dry powder inhaler
Description: Prescribed at ≥twice BDP-equivalent dose as baseline ICS
Study NCT01141465 — intervention group
Intervention type: DRUG
Intervention: Fluticasone / salmeterol metred dose inhaler
Description: Prescribed at ≥twice BDP-equivalent dose as baseline ICS
Study NCT01141465 — intervention group
Intervention type: DRUG
Intervention: BUD/FOR dry powder inhaler
Description: Prescribed at ≥twice BDP-equivalent dose as baseline ICS
Study NCT02063295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 sterile diluent
Description: ZGN-440 sterile diluent/placebo
Study NCT02063295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440 for injectable suspension
Study NCT00973700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
Study NCT00973700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eH1N1_f
Description: Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
Study NCT01894711 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Treatment with trastuzumab in HER2 positive patients
Study NCT00847548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: substance abuse/domestic violence treatment
Description: This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
Study NCT00847548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT addressing partner violence
Description: This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
Study NCT02403752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired PLIE Program
Description: Integrative exercise as described above
Study NCT03757364 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
Study NCT03735758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pazopanib or guideline conform chemotherapy
Description: Pazopanib (800mg/each day) or guideline conform chemotherapy
Study NCT03735758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib or guideline conform chemotherapy
Description: Pazopanib (800mg/each day) or guideline conform chemotherapy
Study NCT02512666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AM4113-N5UT Dino-Lite
Study NCT03165552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute kidney injury education
Description: A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.